Michele Ramirez

Conscientious professional with excellent time management skills. Adept at triaging multiple priorities and eliciting excellence from coworkers. Expert in communicating medical terminology clearly and compassionately to patients, families and other healthcare professionals.

12/2002 - Present  Naples Community Hospital, Naples, FL

12/2002 - present  North Collier Hospital, Naples, FL

12/2002 - present  Physicians Regional Medical Center, Naples, FL

12/2002 - present  Collier Regional Hospitals, Naples, FL

3/2006 - 8/2011  Lee Memorial Hospital, Ft. Myers, FL (associate)

3/2006 - 8/2011  Healthpark Medical Center, Ft. Myers, FL (associate)

3/2009 - 8/2011  Gulf Coast Medical Center, Ft. Myers, FL (associate)

Diplomat, American Board of Internal Medicine

Cancer Committee, Naples Community Hospital, 2012 - 2014, 2016 - 2022

7/13/17 Grand Rounds - "Amyloidosis - The Zebra Hiding in Plain Sight"

11/29/18 Grand Rounds - "Hem/ Onc Emergencies in Hospitalized Patients"

2009 CITI Good Clinical Practices Training

2005 Good Clinical Practices Training

2005 Patient-Oriented Research Basic Training

Sub-investigator: Protocol: H3E-US-JMFX - ALTIMA Plus Gemcitabine as Front-line Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase II Clinical Trial. Eli Lilly; 2004

Sub-Investigator: Protocol: LUN 66 - Phase II Trial of Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer Sarah Cannon Cancer Center; 2004

Sub-Investigator: Protocol: OSI3199g - A Multicenter, Open-Label, Phase IIIb Trial of Tarceva (Erlotinib Hydrochloride) in Patients with Advanced Non-Small Cell Lung Cancer. Genentech, 2004

Sub-Investigator: Protocol: L_9444 - CONCEPT - A Phase IV, randomized, prospective, multicenter comparison of a intermittent schedule of Oxaliplatin (IO) combined with 5-Fluorouracil/ Leucovorin (Folfox)/ Bevacizumab versus the conventional mode of administration of Folfox/ Bevacizumab +/- neuroprophylaxis with calcium/ magnesium for the optimization of first line therapy of metastatic colorectal cancer.

Sub-Investigator: Protocol: 11868 - Open Label, Non-Comparative Treatment Protocol for the use of Sorafenib in Patients with Advanced Renal Cell Carcinoma, Bayer Pharmaceutical, 2005.

Sub-Investigator: Protocol: LUN 92 - A Phase II Trial of First-Line Gemcitabine, Docetaxel and Cetuximab in Patients with Unresectable Stage III or IV Non-Small Cell Lung Cancer.

Sub-Investigator: Protocol: 06-090 - A Phase III Trial of Adjuvant TC versus TAC in early stage HER2-negative breast cancer.

Sub-Investigator: Protocol LUN 160 - A Randomized Double-Blind Placebo-Controlled Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small Cell Lung Cancer.

Sub-Investigator Protocol: LUN 156 - Phase II Study of Irinotecan, Carboplatin, and Sunitinib in the First Line Treatment of Extensive-Stage Small Cell Lung Cancer.

Sub-Investigator: Protocol: BRE154 - A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/ Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients with HER2-Negative Metastatic Breast Cancer.

2001-2002 Designed a successful Clinical Research Protocol investigating use of EGFR inhibitor, Gefitinib, in patients with head and neck cancer at University Hospitals of Cleveland (enrollment began after completion of my fellowship)

Spring 1998 Molecular Biology Research elective, University Hospitals of Cleveland. Learned molecular biology techniques in a lab working on gene therapy research using viral vectors

Fall 1995 Epidemiology elective, Division of TB Elimination, Center for Disease Control and Prevention, Atlanta, GA. Assisted in epidemiologic field investigations and surveillance of mycobacterial disease

Fall 1995 Clinical Research Assistant, Department of Internal Medicine, Northshore University Hospital, Manhasset, NY. Conducted a chart review study of the correlation between breast cancer and thyroid disease

ASCO

ASH

FLASCO

Collier County Medical Society